Conversations in Drug Development Trends

MAY 10, 2024

Over the past two decades, industry-sponsored clinical trials have targeted treatments for BPD, yielding some promising outcomes; however, broader psychiatric research often excludes BPD patients, a trend that extends to the emerging field of psychedelic studies.

Clinical Trials 95

Clinical Trials Trials Treatment Drug Development 95

The Pharma Data

OCTOBER 28, 2021

Bayer will present new renal and cardiovascular (CV) analyses from the comprehensive finerenone (Kerendia®) clinical trial program, including the Phase III FIGARO-DKD and FIDELIO-DKD studies, and the prespecified pooled analysis FIDELITY at the American Society of Nephrology (ASN)’s Kidney Week 2021 from 4-7 November.

Clinical Trials 52

Clinical Trials Trials Disease Hospitals 52

PPD

AUGUST 28, 2024

For many patients, involvement in oncology clinical trials represents a last hope for an effective therapy. This is why oncology trials must be built around patient needs, and sponsors need to balance the complexity of oncology trials with a patient-centric mindset. Many of these patients’ conditions are disabling.

Trials 64

Trials Clinical Trials Drug Development Therapies 64

Quanticate

APRIL 5, 2024

Clinical trial professionals are well aware of the unique challenges presented by oncology, a therapeutic area dedicated to the prevention, diagnosis, and treatment of cancers. In this article, we delve into key CRF design considerations for oncology clinical trials.

Trials 52

Trials Clinical Trials Treatment 52

Conversations in Drug Development Trends

AUGUST 29, 2024

By: Nathan Chadwick, Therapeutic Strategy Lead, Rare Disease Over the last few years in clinical trials, particularly within the rare disease community, a notable shift is underway, where patients and caregivers are taking the lead in reaching out to clinical trial sites rather than the other way around.

Clinical Trials 52

Clinical Trials Trials Disease Drug Development 52

Vial

JUNE 24, 2024

Contract research organizations (CROs) and pharmaceutical companies can leverage these cutting-edge technologies to streamline clinical trials and introduce automation in drug discovery. As clinical trials grow in complexity, the volume of data being gathered and utilized for these studies is expanding.

Clinical Trials 52

Clinical Trials Trials Clinical Research Treatment 52

BioPharma Drive: Drug Pricing

SEPTEMBER 14, 2024

Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet be enough to dispel doubts around TIGIT as a target.

Trials 73

Trials Drugs 73

Conversations in Drug Development Trends

JULY 8, 2024

By: Lisle Kingery, PhD, Therapeutic Strategy Lead, Neuroscience With depression rates at an all-time high and limited new treatments available, depression clinical trials are more important than ever. Treatment Treatment can take various forms, including therapy, medication, a combination of both, or a clinical trial.

Clinical Trials 52

Clinical Trials Trials Treatment Therapies 52

Vial

JUNE 18, 2024

The success of clinical trials hinges on increasing access to participation by all eligible patients, including populations that have been underrepresented due to the barriers highlighted below. Representation, Underrepresentation & Diversity in Clinical Trials Studies indicate a need to increase patient accessibility to clinical trials.

Clinical Trials 52

Clinical Trials Trials Clinical Research Research 52

PPD

OCTOBER 9, 2023

“Patient-centric” is used frequently to describe today’s clinical trial and health care landscape. The industry applauds that point of view and strives to include a patient-centric approach in all aspects of clinical trial designs. Patient centricity has become more than a key consideration.

Clinical Trials 98

Clinical Trials Trials Compliance International 98

PPD

NOVEMBER 7, 2023

Food and Drug Administration (FDA) draft guidance, “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials.” Diversity in Dermatologic Disease Prevalence, Presentation and Outcomes Skin conditions affect all skin types and all racial and ethnic groups.

Clinical Trials 59

Clinical Trials Trials Clinical Research Disease 59

The Pharma Data

NOVEMBER 14, 2020

(Nasdaq: GILD) and Novo Nordisk A/S (NASDAQ Copenhagen: NOVO B) today announced results from a Phase 2 proof-of-concept trial. The results were presented at The Liver Meeting Digital Experience (TLMdX), November 13–16, 2020 (Late Breaker #L02). Across all groups, 5–14% of people discontinued any trial treatment due to AEs.

Trials 52

Trials Science Treatment Disease 52

Advarra

AUGUST 14, 2023

The clinical research industry is only becoming more complex and competitive as organizations are inundated with multiple trials and tight deadlines. The clinical trial process is both expensive and time-consuming, and ends more often in failure than success. of respondents reported they know what clinical trials are.

Clinical Trials 52

Clinical Trials Trials Clinical Research Research 52

The Pharma Data

MAY 14, 2021

Product Name: GlucoFlow – Presentation. Click here to get GlucoFlow – Presentation at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors. Try GlucoFlow for yourself, completely risk free.

Packaging 52

Packaging Production Compliance Regulations 52

The Pharma Data

MAY 26, 2023

Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting will present data across its Oncology portfolio and growing pipeline, covering multiple tumor types and novel mechanisms of action at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2 through June 6.

Biosimilars 52

Biosimilars Clinical Development Science Therapies 52

PPD

MAY 18, 2023

Yet, four out of five care partners of people with neurodegenerative disorders have never been informed of clinical trial opportunities , according to a survey of more than 250 caregivers conducted by PPD, the clinical research business of Thermo Fisher Scientific. There’s little time to lose.

Clinical Trials 86

Clinical Trials Trials Clinical Research Doctors 86

BioPharma Drive: Drug Pricing

JUNE 17, 2024

One expert described trial results presented at EULAR last week as “unprecedented.” ” But reports of relapses in some patients drew questions about the therapies’ ultimate potential.

Disease 139

Disease Therapies Trials 139

PPD

MARCH 21, 2024

When participating in clinical trials, pediatric populations require distinct considerations for their safety and well-being — which can present unique challenges for drug developers. Five Strategies to Tailor Your Pediatric Clinical Trials to the Child’s Needs 1.

Clinical Trials 52

Clinical Trials Trials Drug Development Treatment 52

The Pharma Data

AUGUST 30, 2021

New Kisqali ® (ribociclib)* overall survival (OS) results from MONALEESA-2 trial in HR+/HER2? Health-related quality of life, pain and safety outcomes from phase III VISION trial of investigational radioligand therapy 177 Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. 19, 2:10 PM CEST].

Trials 52

Trials Clinical Trials Production Therapies 52

The Pharma Data

JUNE 7, 2023

The research presented reinforces the efficacy of LUMAKRAS ® /LUMYKRAS ® (sotorasib) in advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC). Reese, M.D., executive vice president of Research and Development at Amgen.

Clinical Trials 40

Clinical Trials Trials Treatment Disease 40

Alta Sciences

NOVEMBER 15, 2023

WATCH PRESENTATION The ability to quantify ASOs accurately and efficiently in dried blood samples means critical patient populations may be more readily accessible for decentralized clinical trials. This can lead to faster, more efficient research and improved patient outcomes. png Tags Bioanalysis

Clinical Trials 40

Clinical Trials Trials Research 40

Fierce BioTech

MAY 16, 2023

Ashley Toye will talk about the ongoing REcovery and survival of STem cell Originated REd cells (RESTORE) clinical trial. The trial will evaluate the safety and performance of the cultured cells’ in each recipient compared to standard RBCs transfused into the same recipient. Click here to login.

Trials 52

Trials Clinical Trials Production 52

The Pharma Data

MAY 22, 2023

DUPIXENT® (DUPILUMAB) LATE-BREAKING PHASE 3 COPD RESULTS PRESENTED AT ATS AND SIMULTANEOUSLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE Regeneron Pharmaceuticals, Inc. The Dupixent Phase 3 results were presented in the 2023 American Thoracic Society (ATS) International Conference session “New England Journal of Medicine and JAMA.

Trials 52

Trials Disease Clinical Trials Therapies 52

Vial

FEBRUARY 21, 2024

Clinical trials are needed to determine whether a medical device can produce sufficient proof of its efficacy. However, medical device sponsors and developers are limited by the complex regulatory processes and the high costs associated with the design of running clinical trials for their products.

Clinical Trials 52

Clinical Trials Trials Compliance Regulations 52

The Pharma Data

MARCH 11, 2021

Eli Lilly and Company (NYSE: LLY) today announced that data from programs across its oncology portfolio and pipeline will be presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, to be held virtually April 10-15, 2021. LY3484356, an oral SERD, is currently being studied in a Phase 1/2 clinical trial.

Research 52

Research Clinical Trials Trials FDA Approval 52

The Pharma Data

APRIL 11, 2023

The presentation highlights the synergistic anti-cancer effects of a PSMA (prostate-specific membrane antigen)-actinium-225 conjugate in combination with darolutamide in preclinical prostate cancer models. Data from all three areas of scientific focus will be showcased during this year’s meeting.

Research 40

Research Clinical Trials Small Molecule Trials 40

The Pharma Data

SEPTEMBER 6, 2021

First data to be presented from the phase II coopERA Breast Cancer study evaluating neoadjuvant giredestrant treatment for oestrogen receptor (ER)-positive, HER2-negative breast cancer. Breast Cancer Highlights. Lung Cancer Highlights.

Treatment 52

Treatment Therapies DNA Trials 52

Advarra

OCTOBER 14, 2022

In the context of decentralized clinical trials (DCTs), we have seen an explosion of new devices and apps interacting with participants and collecting information throughout a trial, all with the participant never setting foot in a traditional clinical research site. What is this innovation?

Clinical Trials 52

Clinical Trials Trials FDA Clinical Research 52

Advarra

JUNE 13, 2024

Recombinant DNA technologies and genetically modified biological agents are being adapted for a wide scope of therapeutic applications, and their use is becoming increasingly common in clinical trials. For example, a site conducting only protocols involving mRNA may be able to leverage a generic SOP covering any mRNA protocol at that site.

Clinical Trials 52

Clinical Trials Engineering Trials Virus 52

PPD

JANUARY 5, 2023

In our survey, patient recruitment and retention remain significant concerns cited by clinical trial sponsors across all therapies. Research by Global Data finds that more than one out of four rare disease clinical trials terminate due to low patient accrual rates. Expand access with decentralized clinical trials (DCTs).

Disease 52

Disease Trials Clinical Trials Clinical Research 52

PPD

JUNE 29, 2023

Finding the right patients, connecting with the right sites and leveraging the right expertise present challenges. To be competitive, drug developers must run their trials efficiently and within budget and timelines, while still maintaining quality to support authorization.

Clinical Trials 52

Clinical Trials Trials Drug Development Clinical Research 52

SCIENMAG: Medicine & Health

OCTOBER 25, 2023

The Global Coalition for Adaptive Research (GCAR) in collaboration with the University of Pittsburgh and UPMC, on behalf of the REMAP-CAP Investigator Network, announce clinical trial results examining the use of vitamin C and simvastatin to treat severely ill patients with COVID-19.

Clinical Trials 52

Clinical Trials Trials Research Drugs 52

The Pharma Data

JULY 29, 2021

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at 2021 Alzheimer’s Association International Conference (AAIC) . United States and virtually from July 26 to 30, 2021 (Presentation No.:

Clinical Trials 52

Clinical Trials Treatment Clinical Development Disease 52

The Pharma Data

JANUARY 10, 2021

Chief Executive Officer of MorphoSys, will present at the 39 th Annual J.P. EST. Live audio of the presentation can be accessed from the Media and Investors section under Conferences on MorphoSys’ website, www.morphosys.com. The presentation as well as a replay of the webcast will also be available on MorphoSys’ website.

Clinical Development 52

Clinical Development Clinical Trials Clinical Supply Trials 52

The Pharma Data

JANUARY 14, 2021

(NASDAQ: FPRX) today announced clinical results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial evaluating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer. The ASCO GI presentation slides are available on the company’s website. Wainberg, M.D.,

Trials 52

Trials Treatment Therapies Clinical Trials 52

The Pharma Data

MAY 31, 2022

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it will present data at two upcoming scientific congresses this spring: the 58 th Annual Meeting of the American Society of Clinical Oncology (ASCO) , June 3-7 in Chicago, Ill. Head of Oncology Cell Therapy and Therapeutic Area Unit of Takeda. “In

Research 40

Research Pharmaceutical Companies Therapies Pharmaceuticals 40

The Pharma Data

NOVEMBER 18, 2020

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort. These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. ” Presentation number: 397P / Poster: ID 680.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52